ConvaTec (GB:CTEC)
LSE:CTEC
Want to see GB:CTEC full AI Analyst Report?
CTEC Stock Chart & Stats
230.00 p
1.06 p(0.47%)
At close: 4:00 PM EST
230.00 p
1.06 p(0.47%)
Day’s Range― - ―
52-Week Range193.00 p - 294.20 p
Previous CloseN/A
Volume85.46K
Average Volume (3M)6.27M
Market Cap
£4.04B
Enterprise Value6.77B
Total Cash (Recent Filing)£75.03M
Total Debt (Recent Filing)£1.52B
Price to Earnings (P/E)30.3
Beta1.04
Next Earnings
Aug 04, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend Yield2.11%
Share Statistics
EPS (TTM)0.09
Shares Outstanding1,954,852,000
10 Day Avg. Volume5,278,857
30 Day Avg. Volume6,266,139
Financial Highlights & Ratios
PEG Ratio-7.33
Price to Book (P/B)4.36
Price to Sales (P/S)2.66
P/FCF Ratio19.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£301.56Price Target Upside31.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)0.2
Revenue Forecast (FY)£2.57B
Bulls Say, Bears Say
Bulls Say
Consistent Organic Revenue GrowthConvaTec's multi-year organic growth record and 2026 guidance (5–7% ex-InnovaMatrix, 6–8% medium term) reflect durable demand for recurring chronic-care consumables and expanding product mix. This underpins predictable revenue streams and supports capacity investments and sustained top-line resilience.
Margin Expansion And ProfitabilityMaterial operating margin improvement (cumulative expansion since 2021) indicates lasting structural gains from pricing, productivity and simplification programs. Higher sustainable operating margins strengthen cash flow generation, funding growth CapEx and returns while providing a buffer against inflation and execution variability.
Strong Cash Generation And Capital AllocationConsistently high free cash flow conversion and active returns (buybacks, dividend growth) show durable cash-generation capacity. Reliable FCF funds growth CapEx, pipeline launches and shareholder returns while supporting leverage targets, giving management flexibility to invest while returning capital to shareholders.
Bears Say
Increased Leverage And Working CapitalHigher leverage reduces financial flexibility and raises sensitivity to earnings shortfalls or rising rates. With net debt up materially and working capital seasonality noted, the company has less headroom for opportunistic M&A or to absorb execution setbacks, increasing refinancing and covenant risk over the medium term.
Regulatory Quality Issues (FDA Warning Letter)An FDA warning on complaints and CAPA is a structural governance and quality-control concern that requires sustained remediation. It can lead to increased compliance costs, slower product launches, deeper inspections, and reputational impacts that persistently raise operating risk and could constrain sales in regulated markets.
InnovaMatrix Reimbursement Shock & ImpairmentThe severe CMS reimbursement cut and resulting impairment show exposure to payer policy shifts that can permanently reduce acquired-product economics. This demonstrates structural reimbursement risk for certain product categories, complicates integration returns and creates medium-term revenue headwinds and channel uncertainty.
ConvaTec News
CTEC FAQ
What was ConvaTec’s price range in the past 12 months?
ConvaTec lowest share price was 193.00 p and its highest was 294.20 p in the past 12 months.
What is ConvaTec’s market cap?
ConvaTec’s market cap is £4.04B.
When is ConvaTec’s upcoming earnings report date?
ConvaTec’s upcoming earnings report date is Aug 04, 2026 which is in 43 days.
How were ConvaTec’s earnings last quarter?
ConvaTec released its earnings results on Feb 24, 2026. The company reported 0.072 p earnings per share for the quarter, missing the consensus estimate of 0.075 p by -0.002 p.
Is ConvaTec overvalued?
According to Wall Street analysts ConvaTec’s price is currently Undervalued.
Does ConvaTec pay dividends?
ConvaTec pays a Semiannually dividend of 3.973 p which represents an annual dividend yield of 2.11%. See more information on ConvaTec dividends here
What is ConvaTec’s EPS estimate?
ConvaTec’s EPS estimate is 0.06.
How many shares outstanding does ConvaTec have?
ConvaTec has 1,954,852,000 shares outstanding.
What happened to ConvaTec’s price movement after its last earnings report?
ConvaTec reported an EPS of 0.072 p in its last earnings report, missing expectations of 0.075 p. Following the earnings report the stock price went up 10.397%.
Which hedge fund is a major shareholder of ConvaTec?
Currently, no hedge funds are holding shares in GB:CTEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ConvaTec Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
£301.56 (31.11% Upside)
£301.56 (31.11% Upside)
Insider Transactions
Bought Shares
Worth £150.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.61%
12-Months-Change
Fundamentals
Return on Equity
10.53%
Trailing 12-Months
Asset Growth
0.16%
Trailing 12-Months
Company Description
ConvaTec
ConvaTec Group Plc operates as a global medical technology company, specializing in the creation, production, and worldwide distribution of a diverse array of healthcare products. Its offerings span critical areas, including advanced wound care, where it provides specialized dressings and skin care items for managing acute and chronic wounds that arise from conditions like diabetes, immobility, venous disease, traumatic injuries, burns, or surgical recovery. The company is also a key provider in ostomy care, delivering essential devices, accessories, and support services for individuals living with a stoma due to conditions such as colorectal cancer, inflammatory bowel disease, bladder cancer, and obesity. Beyond wound and ostomy solutions, ConvaTec's portfolio extends to continence and critical care. This includes intermittent urinary catheters and related products designed to assist individuals with urinary continence issues stemming from spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders. They also furnish equipment for intensive care units and hospital settings, alongside advanced systems for managing acute fecal incontinence and monitoring urine output and intra-abdominal pressure. Additionally, ConvaTec supplies various disposable medical devices, such as wound drainage systems, urine collection bags, airway management tools, gastroenterology tubes, and securement devices. The company manufactures disposable infusion sets for insulin pumps used in diabetes treatment, as well as for other continuous infusion therapies. These products reach pharmacies, hospitals, and both acute and post-acute healthcare providers directly, or through a network of distributors and wholesalers, catering to healthcare professionals, patients, and other manufacturers. Established in 1978, ConvaTec Group Plc is headquartered in Reading, United Kingdom.
CTEC Stock 12 Month Forecast
Average Price Target
301.56 p
▲(31.11% Upside)
Technical Analysis
Options Prices
Currently, No data available
---